<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03304457</url>
  </required_header>
  <id_info>
    <org_study_id>T/IM-F/17-18/29</org_study_id>
    <nct_id>NCT03304457</nct_id>
  </id_info>
  <brief_title>Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia</brief_title>
  <official_title>Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia (SCZ) is a chronic, severe and disabling mental disorder with unclear etiology
      and pathophysiology concerned with neuro-developmental,neurodegenerative abnormalities and
      cognitive impairmentslinked to behavioural changes.According to neurotrophic hypothesis, the
      changes result due to the abnormal regulation of neurotrophic factor, especially the
      decreased serum brain derived neurotrophic factor (BDNF) validated by several meta-analyses.
      However, the regulation of nerve growth factor (NGF) in SCZ remains unclear because of the
      inconsistent findings from the previous clinical studies.

      Lurasidone is a novel antipsychotic drug approved for adult SCZ and for affective
      symptomatology &amp; cognitive deficits. Principal advantages over some other second-generation
      antipsychotics are its highly favourable metabolic profile and once daily dosing regimen.
      Some of the studies indicate that risperidone, olanzapine, clozapine &amp; aripiprazole might not
      alter BDNF levels, at least within 8 weeks of treatment.While other two studies with
      olanzapine suggest that BDNF might influence the response to monotherapy in SCZ patients.All
      these previous studies are non-conclusive &amp; contradictory to each other which draw our
      attention for doing the research further to reach a conclusive result about the effect of
      olanzapine and lurasidone on neurotrophic biomarkers in SCZ.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia (SCZ) is a chronic, severe and disabling mental disorder with unclear aetiology
      and pathophysiology concerned with neuro-developmental,neurodegenerative abnormalities and
      cognitive impairments linked to behavioural changes.According to neurotrophic hypothesis, the
      changes result due to the abnormal regulation of neurotrophic factor, especially the
      decreased serum brain derived neurotrophic factor (BDNF) validated by several meta-analyses.
      However, the regulation of nerve growth factor (NGF) in SCZ remains unclear because of the
      inconsistent findings from the previous clinical studies.

      Lurasidone is a novel antipsychotic drug approved for adult SCZ and for affective
      symptomatology &amp; cognitive deficits. Principal advantages over some other second-generation
      antipsychotics are its highly favourable metabolic profile and once daily dosing regimen.
      Some of the studies indicate that risperidone, olanzapine, clozapine &amp; aripiprazole might not
      alter BDNF levels, at least within 8 weeks of treatment.While other two studies with
      olanzapine suggest that BDNF might influence the response to monotherapy in SCZ patients.All
      these previous studies are non-conclusive &amp; contradictory to each other which draw our
      attention for doing the research further to reach a conclusive result about the effect of
      olanzapine and lurasidone on neurotrophic biomarkers in SCZ.

      Most of the antipsychotic drugs prescribed for SCZ are based on the dopamine hypothesis. In
      recent times, neurotrophic hypothesis gained importance in the pathophysiology of SCZ. So,
      our study may enable psychiatrist to choose a better antipsychotic drug having effect on both
      dopamine as well as neurotrophic factors. Previously there were no studies on effect of
      lurasidone on neurotrophic factors in SCZ &amp; also there was no head-on comparison of
      lurasidone and olanzapine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2017</start_date>
  <completion_date type="Actual">March 25, 2018</completion_date>
  <primary_completion_date type="Actual">March 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, open label, active controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum brain derive neurotrophic factor (BDNF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>the change in serum level of BDNF from baseline after treatment with lurasidone or olanzapine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum nerve growth factor (NGF)</measure>
    <time_frame>6 weeks</time_frame>
    <description>the change in serum level of NGF from baseline after treatment with lurasidone or olanzapine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Neurotrophin 3 (NT3)</measure>
    <time_frame>6 weeks</time_frame>
    <description>the change in serum level of NT3 from baseline after treatment with lurasidone or olanzapine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS score</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the association (if any) between change in serum neurotrophic factor and PANSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social and occupational functioning assessment scale (SOFAS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the association (if any) between change in serum neurotrophic factor and SOFAS (Social and occupational functioning assessment scale) score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 10mg once daily orally for 6 weeks</description>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Lurasidone 80mg once daily orally for 6 weeks</description>
    <arm_group_label>Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All treatment naive patients clinically diagnosed first episode of SCZ according to
             ICD-10

          -  Patients of either sex with age range 18-45 years

          -  Treatment na√Øve patients

        Exclusion Criteria:

          -  Other Psychotic spectrum disorders (F21- F29)

          -  Highly agitated/ violent/ suicidal patients who need immediate treatment

          -  Patients with comorbid substance abuse except Nicotine use or history of organicity

          -  Patients with known history of diabetes mellitus, hypertension or any long standing
             significant medical illness/ significant neurological impairment/ clinical observable
             mental retardation

          -  Pregnant and nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debasish Hota, MD, DM</last_name>
    <role>Study Director</role>
    <affiliation>Professor &amp; Head</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIIMS</name>
      <address>
        <city>Bhubaneshwar</city>
        <state>Odisha</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull. 2008 Nov;34(6):1066-82. doi: 10.1093/schbul/sbn117. Epub 2008 Sep 12. Review.</citation>
    <PMID>18791076</PMID>
  </results_reference>
  <results_reference>
    <citation>Gejman PV, Sanders AR, Kendler KS. Genetics of schizophrenia: new findings and challenges. Annu Rev Genomics Hum Genet. 2011;12:121-44. doi: 10.1146/annurev-genom-082410-101459. Review.</citation>
    <PMID>21639796</PMID>
  </results_reference>
  <results_reference>
    <citation>Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry. 2011 Mar;198(3):173-5. doi: 10.1192/bjp.bp.110.084384.</citation>
    <PMID>21357874</PMID>
  </results_reference>
  <results_reference>
    <citation>Ashe PC, Berry MD, Boulton AA. Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):691-707. Review.</citation>
    <PMID>11383973</PMID>
  </results_reference>
  <results_reference>
    <citation>P√©rez-Neri I, Ram√≠rez-Berm√∫dez J, Montes S, R√≠os C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res. 2006 Oct;31(10):1279-94. Epub 2006 Sep 28. Review.</citation>
    <PMID>17006758</PMID>
  </results_reference>
  <results_reference>
    <citation>Matza LS, Buchanan R, Purdon S, Brewster-Jordan J, Zhao Y, Revicki DA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull. 2006 Oct;32(4):666-78. Epub 2006 Jul 7. Review.</citation>
    <PMID>16829550</PMID>
  </results_reference>
  <results_reference>
    <citation>Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 2015 Mar 30;226(1):1-13. doi: 10.1016/j.psychres.2014.12.069. Epub 2015 Jan 28. Review.</citation>
    <PMID>25681004</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):256-61. doi: 10.3109/15622970802309617.</citation>
    <PMID>20218790</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, Nakano Y, Shinkai K, Mitoma M, Ohta M, Shinkai T, Nakamura J. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1072-7. Epub 2007 Mar 24.</citation>
    <PMID>17459549</PMID>
  </results_reference>
  <results_reference>
    <citation>Hori H, Yoshimura R, Yamada Y, Ikenouchi A, Mitoma M, Ida Y, Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007 Jan;22(1):21-7.</citation>
    <PMID>17159456</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A, Kozumplik O, Muck-Seler D, Pivac N. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology (Berl). 2014 Sep;231(18):3757-64. doi: 10.1007/s00213-014-3515-4. Epub 2014 Mar 5.</citation>
    <PMID>24595507</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonz√°lez-Pinto A, Mosquera F, Palomino A, Alberich S, Guti√©rrez A, Haidar K, Vega P, Barbeito S, Ortiz A, Matute C. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2010 Jul;25(4):241-5.</citation>
    <PMID>20568658</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>Dr. Monalisa Jena, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Lurasidone</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>Brain derived neurotrophic factor</keyword>
  <keyword>Nerve growth factor</keyword>
  <keyword>Neurotrophin 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

